Protein Kinase Inhibitors: all 15,278 studies that test it
Page 100 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.
- Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF MutationsActive, not recruitingNCT03839342Phase 2
- Ponatinib in Advanced or Metastatic Medullary Thyroid CancerWithdrawnNCT03838692Phase 2
- (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial CancerActive, not recruitingNCT03837821Early Phase 1
- BTK Inhibitor DTRMWXHS-12 in Mantle Cell LymphomaCompletedNCT03836768Phase 1
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceActive, not recruitingNCT03833440Phase 2
- FGFR Inhibitor in FGFR Dysregulated CancerTerminatedNCT03827850Phase 2
- A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTSCompletedNCT03827668Phase 1
- Ibrutinib in Steroid Refractory Autoimmune Hemolytic AnemiaStatus unknownNCT03827603Phase 2
- Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung CarcinomaStatus unknownNCT03827070Phase 1
- Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and ChildrenCompletedNCT03826901Phase 1
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on MetforminCompletedNCT03826602Phase 1
- Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based ChemotherapyCompletedNCT03826589Not applicable
- A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular CarcinomaStatus unknownNCT03825705Phase 1/2
- Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic CancerTerminatedNCT03825289Phase 1
- hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"Status unknownNCT03824691Phase 2
- Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)Active, not recruitingNCT03824483Phase 2
- Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic SyndromesCompletedNCT03824080Phase 2
- S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung CancerCompletedNCT03823118Phase 2
- Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy ParticipantsCompletedNCT03821493Phase 1
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerActive, not recruitingNCT03820830Phase 3
- Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ CancerStatus unknownNCT03817411Phase 2
- Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma PatientsStatus unknownNCT03815474Phase 2
- A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation PositiveCompletedNCT03812809Phase 2
- Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative BreastActive, not recruitingNCT03812393Phase 2
- An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 MutationStatus unknownNCT03810872Phase 2
- Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerCompletedNCT03810807Phase 1
- Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)CompletedNCT03810066Phase 2
- PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)CompletedNCT03809988Phase 2
- Study in Patients With Chronic LeukemiaTerminatedNCT03807479Phase 2
- Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy ParticipantsCompletedNCT03806101Phase 1
- Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell TransplantationCompletedNCT03805477Phase 2
- FUSCC Refractory TNBC Umbrella (FUTURE)Status unknownNCT03805399Phase 1/2
- First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung CancerActive, not recruitingNCT03804580Phase 2
- The Absorption, Metabolism and Excretion of [14C]Ensartinib in HumanStatus unknownNCT03804541Phase 1
- A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerWithdrawnNCT03803761Phase 1/2
- Lenvatinib for Unresectable Intrahepatic CholangiocarcinomaWithdrawnNCT03801499Phase 2
- Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic DisordersActive, not recruitingNCT03801434Phase 2
- Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLCStatus unknownNCT03801200Phase 2
- Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLCStatus unknownNCT03799601Phase 4
- A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue SarcomaCompletedNCT03798106Phase 2
- A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)CompletedNCT03797456Phase 2
- Ruxolitinib Combined With Dexamethasone for HLHStatus unknownNCT03795909Phase 1/2
- Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 MutationsWithdrawnNCT03794297Phase 2
- Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodActive, not recruitingNCT03793478Phase 1/2
- Phase II Study of Regorafenib as Maintenance TherapyCompletedNCT03793361Phase 2
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyActive, not recruitingNCT03793166Phase 3
- Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid TumorsStatus unknownNCT03792958Phase 1
- Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive ChemotherapyStatus unknownNCT03792542Phase 2
- Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based RegimenWithdrawnNCT03792503Phase 4
- Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALSCompletedNCT03792490Phase 2
- Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03791918Phase 3
- A Phase I Study of BPI-16350 in Patients with Advanced Solid TumorActive, not recruitingNCT03791112Phase 1
- Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)CompletedNCT03790332Phase 1/2
- Rogaratinib (BAY1163877) in Chinese PatientsCompletedNCT03788603Phase 1
- Apatinib Combined With POF for Second-line Treatment of Gastric AdenocarcinomaStatus unknownNCT03788174Phase 2
- Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLLCompletedNCT03787264Phase 2
- A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With ApatinibWithdrawnNCT03787251Phase 2
- T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCTerminatedNCT03784599Phase 2
- Continued Access to RXDX-105CompletedNCT03784378Phase 1
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
- Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung CancerStatus unknownNCT03781869Phase 2
- Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers SyndromeStatus unknownNCT03781050Phase 4
- This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)Status unknownNCT03780608Phase 2
- Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered TumorsCompletedNCT03780517Phase 1
- Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLCStatus unknownNCT03780283Phase 2
- A Study of the Safety and Tolerability of INCB050465 in Pemphigus VulgarisWithdrawnNCT03780166Phase 2
- Alectinib in Combination With Bevacizumab in ALK Positive NSCLCCompletedNCT03779191Phase 2
- Lenvatinib Plus PD-1 Antibody for Unresectable ICCSuspendedNCT03779100Phase 2
- Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)Status unknownNCT03778853Phase 4
- Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLCStatus unknownNCT03778138Phase 2
- Effects of Tucatinib on Cardiac Repolarization in Healthy ParticipantsCompletedNCT03777761Phase 1
- A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1CompletedNCT03776071Phase 3
- Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast CancerStatus unknownNCT03775928Phase 2
- Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven CriteriaWithdrawnNCT03775707Phase 2
- HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCCStatus unknownNCT03775395Phase 3
- Multicenter Study of Seliciclib (R-roscovitine) for Cushing DiseaseCompletedNCT03774446Phase 2
- Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast CancerActive, not recruitingNCT03772353Phase 1/2
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)WithdrawnNCT03772288Phase 1
- Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil LevelsCompletedNCT03771040Phase 3
- A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)Status unknownNCT03770988Phase 2
- AZD6738 for Patients With Progressive MDS or CMMLActive, not recruitingNCT03770429Phase 1
- Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaCompletedNCT03770416Phase 2
- Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLCStatus unknownNCT03769805Not applicable
- Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLCActive, not recruitingNCT03769103Phase 2
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
- Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLCStatus unknownNCT03768037Phase 4
- Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous MalformationStatus unknownNCT03767660Phase 4
- Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT03766776Not applicable
- Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung CancerStatus unknownNCT03766490Not applicable
- Masitinib Plus Gemcitabine in Pancreatic CancerCompletedNCT03766295Phase 3
- Bioequivalence Study of NPC-12 (Sirolimus) Granules and TabletsCompletedNCT03765944Phase 1
- Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M NegativeStatus unknownNCT03765775Phase 2
- Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different FormulationsCompletedNCT03765554Phase 1
- Nilotinib in Huntington's DiseaseStatus unknownNCT03764215Phase 1
- ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZCompletedNCT03762928Phase 1
- Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)TerminatedNCT03762122Phase 2
- Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate CancerCompletedNCT03761225Phase 3
- Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute LeukemiasTerminatedNCT03761069Phase 1
- Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M MutationStatus unknownNCT03758677Phase 2